Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & ObjectivesMission StatementEditorial BoardPartnership & OutreachForthcoming Meetings

Question of the Month

What’s new on the horizon for lipoprotein(a) therapies?

Prof Henry Ginsberg

Prof Henry Ginsberg (Columbia University, New York, USA) overviews the latest news in novel Lp(a) therapies.
Watch video »

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »

News from the Trials

Keep up to date with latest news and analyses from PCSK9 inhibitor trials.

View latest news »

Trial Resources

For expert analysis and insights

View Trials »

View Trial slide decks »

Most viewed
Most viewed

From the Editors

Lipoprotein(a) and atrial fibrillation – Is there a link?

John chapman & Henry GinsbergProfs. John Chapman and Henry Ginsberg discuss new data implicating Lp(a) as a potential causal mediator of atrial fibrillation.

Read the editorial

Related reports:

Updated lipoprotein(a) consensus paper

Keynote – Lipoprotein(a): “The proof of the pudding is in the trial”

Does PCSK9 inhibition reduce the risk of venous thromboembolism?

Meet our Editorial Board

View all our Editorial Board Prof John ChapmanResearch Professor at the Sorbonne University Prof Henry GinsbergIrving Professor of Medicine, Columbia University Dr Michel FarnierClinician based at Point Medical, Dijon, France Prof Frederick RaalDirector, Carbohydrate & Lipid Metabolism Research Unit Prof Anthony WierzbickiConsultant in Metabolic Medicine/Chemical Pathology